Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 3 versus THYROLAR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 3 versus THYROLAR 5.
THYROLAR-3 vs THYROLAR-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
Thyrolar-5 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to T3 in peripheral tissues. T3 binds to thyroid hormone receptors, regulating gene transcription and increasing cellular metabolism.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
Oral, starting dose 15-30 mg daily, titrated to maintenance dose of 60-120 mg daily, divided into 2-3 doses.
None Documented
None Documented
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Liothyronine (T3): 1-2 days; Levothyroxine (T4): 6-7 days. Clinical context: In hyperthyroidism, T4 half-life shortens to 3-4 days; in hypothyroidism, prolongs to 9-10 days
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Renal: 40-50% (as conjugated metabolites); Fecal: 20-30% (enterohepatic recirculation); Biliary: minor
Category C
Category C
Thyroid Hormone
Thyroid Hormone